Insider Transactions in Q1 2024 at Igm Biosciences, Inc. (IGMS)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 29
2024
|
Michael Stewart Lee Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,734
+22.85%
|
-
|
|
Mar 29
2024
|
Elizabeth H.Z. Thompson |
BUY
Grant, award, or other acquisition
|
Direct |
1,452
+50.0%
|
-
|
|
Mar 29
2024
|
Christina Teng Topsoe |
BUY
Grant, award, or other acquisition
|
Direct |
2,687
+5.8%
|
-
|
|
Mar 29
2024
|
Jakob Haldor Topsoe |
BUY
Grant, award, or other acquisition
|
Direct |
1,734
+2.0%
|
-
|
|
Mar 29
2024
|
M Kathleen Behrens |
BUY
Grant, award, or other acquisition
|
Direct |
3,078
+23.45%
|
-
|
|
Mar 29
2024
|
Redmile Group, LLC Director |
BUY
Grant, award, or other acquisition
|
Indirect |
1,734
+0.06%
|
-
|
|
Mar 29
2024
|
Baker Bros. Advisors LP |
BUY
Grant, award, or other acquisition
|
Indirect |
3,988
+0.31%
|
-
|
|
Mar 28
2024
|
Redmile Group, LLC Director |
SELL
Other acquisition or disposition
|
Indirect |
12,464
-0.4%
|
-
|
|
Mar 28
2024
|
Baker Bros. Advisors LP |
BUY
Open market or private purchase
|
Indirect |
97,473
+2.3%
|
$877,257
$9.62 P/Share
|
|
Mar 27
2024
|
Baker Bros. Advisors LP |
BUY
Open market or private purchase
|
Indirect |
27,844
+0.34%
|
$250,596
$9.25 P/Share
|
|
Mar 26
2024
|
Fred Schwarzer CEO AND PRESIDENT |
BUY
Grant, award, or other acquisition
|
Direct |
38,583
+13.13%
|
-
|
|
Mar 26
2024
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
24,019
+10.92%
|
-
|
|
Mar 26
2024
|
Baker Bros. Advisors LP |
BUY
Open market or private purchase
|
Indirect |
270,000
+6.3%
|
$2,160,000
$8.26 P/Share
|
|
Mar 14
2024
|
Chris H Takimoto CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,535
-2.62%
|
$25,350
$10.17 P/Share
|
|
Mar 14
2024
|
Steven Weber PRINCIPAL ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
464
-1.72%
|
$4,640
$10.17 P/Share
|
|
Mar 14
2024
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
1,844
-1.06%
|
$18,440
$10.17 P/Share
|
|
Mar 14
2024
|
Fred Schwarzer CEO AND PRESIDENT |
SELL
Open market or private sale
|
Direct |
4,182
-1.89%
|
$41,820
$10.17 P/Share
|
|
Mar 14
2024
|
Misbah Tahir CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,543
-2.74%
|
$25,430
$10.17 P/Share
|
|
Mar 14
2024
|
Lisa Lynn Decker CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Direct |
1,578
-2.52%
|
$15,780
$10.17 P/Share
|
|
Mar 13
2024
|
Chris H Takimoto CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,889
-2.89%
|
$26,001
$9.88 P/Share
|
|
Mar 13
2024
|
Steven Weber PRINCIPAL ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
529
-1.92%
|
$4,761
$9.88 P/Share
|
|
Mar 13
2024
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
2,101
-1.2%
|
$18,909
$9.88 P/Share
|
|
Mar 13
2024
|
Fred Schwarzer CEO AND PRESIDENT |
SELL
Open market or private sale
|
Direct |
4,765
-2.11%
|
$42,885
$9.88 P/Share
|
|
Mar 13
2024
|
Misbah Tahir CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,897
-3.02%
|
$26,073
$9.88 P/Share
|
|
Mar 13
2024
|
Lisa Lynn Decker CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Direct |
1,798
-2.79%
|
$16,182
$9.88 P/Share
|
|
Mar 12
2024
|
Chris H Takimoto CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
46,250
+31.66%
|
-
|
|
Mar 12
2024
|
Steven Weber PRINCIPAL ACCOUNTING OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
18,750
+40.54%
|
-
|
|
Mar 12
2024
|
Misbah Tahir CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
46,250
+32.55%
|
-
|
|
Mar 12
2024
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
46,250
+20.83%
|
-
|
|
Mar 12
2024
|
Fred Schwarzer CEO AND PRESIDENT |
BUY
Grant, award, or other acquisition
|
Direct |
122,750
+35.24%
|
-
|
|
Mar 12
2024
|
Lisa Lynn Decker CHIEF BUSINESS OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
28,750
+30.87%
|
-
|
|
Mar 01
2024
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Indirect |
3,026
+42.83%
|
$0
$0.93 P/Share
|
|
Feb 28
2024
|
Redmile Group, LLC Director |
BUY
Conversion of derivative security
|
Indirect |
113,400
+3.54%
|
-
|